|
Malignant neoplasm of colon and/or rectum
|
0.060 |
GeneticVariation
|
disease |
BEFREE |
Promoter SNPs rs116896264 and rs73933062 form a distinct haplotype and are associated with galectin-4 overexpression in colorectal cancer.
|
26681582 |
2016 |
|
Tumor Progression
|
0.040 |
GeneticVariation
|
phenotype |
BEFREE |
To facilitate phenotypic analysis of tumor progression in imaginal discs, here we describe a protocol for genetic experiments using the GAL4-UAS system to induce neoplastic tumors in wing imaginal discs.
|
28784954 |
2017 |
|
Secondary malignant neoplasm of lymph node
|
0.030 |
GeneticVariation
|
disease |
BEFREE |
The promoter hypermethylation of LGALS4 (>2.51, log10 scale) revealed a positive correlation with high levels of both histological grade and tumor T category and with lymph node metastasis (all P≤0.001).
|
28423602 |
2017 |
|
Malignant neoplasm of breast
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
Stable transfection of the chimeric Gal4 estrogen receptor and luciferase gene constructs in MCF-7 breast cancer and Hepa.1c1c7 mouse hepatoma cell lines, as well as transfection of a newly constructed luciferase reporter gene pEREtata-Luc in the ECC-1 human endometrial cell line, resulted in constitutive, non-estradiol-inducible clones.
|
10330684 |
1999 |
|
Adenocarcinoma of pancreas
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
Galectine-4 (gal-4), encoded by the LGALS4 gene, was recently shown to exhibit a tumor suppressive effect in colorectal carcinoma and pancreatic adenocarcinoma, although how the expression of this gene is regulated remains unknown.
|
28423602 |
2017 |
|
Breast Carcinoma
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
Stable transfection of the chimeric Gal4 estrogen receptor and luciferase gene constructs in MCF-7 breast cancer and Hepa.1c1c7 mouse hepatoma cell lines, as well as transfection of a newly constructed luciferase reporter gene pEREtata-Luc in the ECC-1 human endometrial cell line, resulted in constitutive, non-estradiol-inducible clones.
|
10330684 |
1999 |
|
Amyotrophic Lateral Sclerosis
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
We prepared transgenic Drosophila expressing either the wild type (Wt) or ALS-mutant human FUS protein (hFUS) using the UAS-Gal4 system.
|
21748598 |
2011 |
|
Diabetes
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Galectin-4, with an increased risk of diabetes, and Paraoxonase type 3, with a decreased risk of diabetes, remained significantly associated with incident diabetes after adjusting for plasma glucose, implying a glucose independent association with diabetes.
|
30670722 |
2019 |
|
Diabetes Mellitus
|
0.010 |
GeneticVariation
|
group |
BEFREE |
Galectin-4, with an increased risk of diabetes, and Paraoxonase type 3, with a decreased risk of diabetes, remained significantly associated with incident diabetes after adjusting for plasma glucose, implying a glucose independent association with diabetes.
|
30670722 |
2019 |
|
Diphtheria
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
The yeast Gal4 DNA-binding domain enabled specific binding of DNA while the translocation domain from diphtheria toxin (DT) was included to facilitate crossing of the endosomal vesicle.
|
14668054 |
2003 |
|
Fragile X Syndrome
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
Here we describe some of the methods that have been used to study FXS, ranging from reverse genetic screening using the GAL4-UAS system, to mushroom body staining and courtship behavioral assays to examine the learning and memory deficits associated with FXS.
|
30900182 |
2019 |
|
Hepatitis C
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
The hepatitis C virus (HCV) nonstructural region 5A (NS5A) protein, without its 146 amino-terminal amino acids and fused to the DNA-binding domain of GAL4, strongly activates transcription in yeast and human hepatoma cells.
|
9343247 |
1997 |
|
Memory impairment
|
0.010 |
GeneticVariation
|
phenotype |
BEFREE |
Here we describe some of the methods that have been used to study FXS, ranging from reverse genetic screening using the GAL4-UAS system, to mushroom body staining and courtship behavioral assays to examine the learning and memory deficits associated with FXS.
|
30900182 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
EYA2 was found to function as transcriptional activator in ovarian cancer cells by Gal4 assay and to promote tumor growth in vivo in xenograft models.
|
15705892 |
2005 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
LGALS4, encoding a galactoside-binding protein involved in cell-cell and cell-matrix interactions, was recently shown to be a tumor suppressor in colorectal cancer.
|
22613842 |
2012 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
With the example of gal-4 which functions as a tumor suppressor in CRC cells, we were able to prove that cell surface binding of the lectin not only markedly influences the cell proteome, but also has a bearing on malignancy-associated intracellular protein phosphorylation.
|
30550624 |
2019 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
Immunohistochemistry was performed for LGALS4 (Galectin 4), ACS5 (Acyl-CoA synthetase) and CLU (Clusterin) proteins: LGALS4 was highly up-regulated, particularly in the most differentiated tumors, while CLU was lost in all tumors.
|
19903339 |
2009 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
To facilitate phenotypic analysis of tumor progression in imaginal discs, here we describe a protocol for genetic experiments using the GAL4-UAS system to induce neoplastic tumors in wing imaginal discs.
|
28784954 |
2017 |
|
Neoplasms
|
0.100 |
Biomarker
|
group |
BEFREE |
This study also shows that gal-4 exhibits tumor suppressive effects in CRC cells in vitro.
|
21064109 |
2011 |
|
Colorectal Carcinoma
|
0.070 |
Biomarker
|
disease |
BEFREE |
The goal of this work was to determine the function of gal-4 in CRC.
|
21064109 |
2011 |
|
Colorectal Carcinoma
|
0.070 |
Biomarker
|
disease |
BEFREE |
LGALS4, encoding a galactoside-binding protein involved in cell-cell and cell-matrix interactions, was recently shown to be a tumor suppressor in colorectal cancer.
|
22613842 |
2012 |
|
Colorectal Carcinoma
|
0.070 |
Biomarker
|
disease |
BEFREE |
Galectine-4 (gal-4), encoded by the LGALS4 gene, was recently shown to exhibit a tumor suppressive effect in colorectal carcinoma and pancreatic adenocarcinoma, although how the expression of this gene is regulated remains unknown.
|
28423602 |
2017 |
|
Malignant Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
Furthermore, galectin-4 engaged with C1GALT1-dependent O-glycans to promote castration resistance and metastasis by activating receptor tyrosine kinase signaling and cancer cell stemness properties mediated by SRY-box 9 (SOX9).
|
29906246 |
2018 |
|
Malignant Neoplasms
|
0.060 |
Biomarker
|
group |
BEFREE |
Detection of malignancy-associated phosphoproteome changes in human colorectal cancer induced by cell surface binding of growth-inhibitory galectin-4.
|
30550624 |
2019 |
|
Primary malignant neoplasm
|
0.060 |
Biomarker
|
group |
BEFREE |
Furthermore, galectin-4 engaged with C1GALT1-dependent O-glycans to promote castration resistance and metastasis by activating receptor tyrosine kinase signaling and cancer cell stemness properties mediated by SRY-box 9 (SOX9).
|
29906246 |
2018 |